Patents by Inventor Cynthia Sung

Cynthia Sung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11219616
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: January 11, 2022
    Assignees: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
  • Publication number: 20200338050
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.
    Type: Application
    Filed: December 23, 2019
    Publication date: October 29, 2020
    Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
  • Patent number: 10517854
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: December 31, 2019
    Assignees: 60 Degrees Pharmaceuticals LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
  • Publication number: 20180064693
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV-4 viral infections.
    Type: Application
    Filed: September 18, 2017
    Publication date: March 8, 2018
    Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong OOI, Jenny Low
  • Patent number: 9763921
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 19, 2017
    Assignees: 60 Degrees Pharmaceuticals LLC, Singapore Health Services PTE LTD, National University Of Singapore
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
  • Publication number: 20160158146
    Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.
    Type: Application
    Filed: February 17, 2016
    Publication date: June 9, 2016
    Inventors: Michael R. Robinson, Karl G. Csaky, Robert B. Nussenblatt, Janine A. Smith, Peng Yuan, Cynthia Sung, Matthew P. Fronheiser, Hyuncheol Kim
  • Publication number: 20160030403
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. DOW, Subhash VASUDEVAN, Mark REID, Glynn MORRISH, Cynthia SUNG, Abhay RATHORE, Satoru WATANABE, Eng Eong OOI, Jenny LOW
  • Publication number: 20100272777
    Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.
    Type: Application
    Filed: December 28, 2009
    Publication date: October 28, 2010
    Applicants: Department of Health
    Inventors: Michael R. Robinson, Karl G. Csaky, Robert B. Nussenblatt, Janine A. Smith, Peng Yuan, Cynthia Sung, Matthew P. Fronheiser, Hyuncheol Kim
  • Patent number: 7658364
    Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: February 9, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael R. Robinson, Karl G. Csaky, Robert B. Nussenblatt, Janine A. Smith, Peng Yuan, Cynthia Sung, Matthew P. Fronheiser, Hyuncheol Kim
  • Publication number: 20070190111
    Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.
    Type: Application
    Filed: April 24, 2007
    Publication date: August 16, 2007
    Applicant: Govemment of the U.S.A, represented by the Secretary, Department. of Health and Human
    Inventors: Michael Robinson, Karl Csaky, Robert Nussenblatt, Janine Smith, Peng Yuan, Cynthia Sung, Matthew Fronheiser, Hyuncheol Kim
  • Publication number: 20040180075
    Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.
    Type: Application
    Filed: May 3, 2004
    Publication date: September 16, 2004
    Inventors: Michael R. Robinson, Karl G. Csaky, Robert B. Nussenblatt, Janine A Smith, Peng Yuan, Cynthia Sung, Matthew P. Fronheiser, Hyuncheol Kim
  • Patent number: 6713081
    Abstract: Ocular implant devices for the delivery of a therapeutic agent to an eye in a controlled and sustained manner. Dual mode and single mode drug delivery devices are illustrated and described. Implants suitable for subconjunctival placement are described. Implants suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices that are presented herein.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: March 30, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael R. Robinson, Karl G. Csaky, Peng Yuan, Cynthia Sung, Robert B. Nussenblatt, Janine A. Smith
  • Publication number: 20030175324
    Abstract: Ocular implant devices for the delivery of a therapeutic agent to an eye in a controlled and sustained manner. Dual mode and single mode drug delivery devices are illustrated and described. Implants suitable for subconjunctival placement are described. Implants suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices that are presented herein.
    Type: Application
    Filed: March 15, 2001
    Publication date: September 18, 2003
    Inventors: Michael R. Robinson, Karl G. Csaky, Peng Yuan, Cynthia Sung, Robert B. Nussenblatt, Janine A. Smith
  • Patent number: 4910015
    Abstract: A crosslinked polymer network comprising the reaction product of a polyethylene oxide and a polyglycidoxypropylsiloxane is described. These materials form hydrogel networks having very high partition coefficients for selected pharmaceuticals and are suitable for controlled drug release and water purification.
    Type: Grant
    Filed: October 19, 1987
    Date of Patent: March 20, 1990
    Assignee: Massachusetts Institute of Technology
    Inventors: Cynthia Sung, Edward W. Merrill
  • Patent number: 4906465
    Abstract: A crosslinked polymer network comprising the reaction product of a polyethylene oxide and a polyglycidoxypropylsiloxane is described. These materials demonstrate low in vivo platelet retention as well as a low thrombogenicity. As such, they can provide antithrombogenic properties to blood contacting devices such as catheters, artificial hearts, ventricular grafts and cardiovascular suture.
    Type: Grant
    Filed: March 16, 1988
    Date of Patent: March 6, 1990
    Assignee: Massachusetts Institute of Technology
    Inventors: Elliot L. Chaikof, Cynthia Sung, Edward W. Merrill